At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,660 enrolled
Drug / intervention
Secukinumabdrug
Likely dose
Secukinumab 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Prospective, Non-randomized, Multicenter Study to Evaluate Clear Skin Effect on Health Related Quality of Life Outcomes at 16 and 52 Weeks in Patients With Moderate to Severe Plaque Psoriasis Treated With Secukinumab 300 mg s.c. With or Without Previous Exposure to Systemic Therapy.
In Brief
A Phase 4 clinical trial evaluating Secukinumab for Plaque Psoriasis. Completed, enrolled 1,660 participants across 215 sites in 17 countries.
Detailed Summary
Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis in patients with or without prior exposure to systemic therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesBelgium, Bulgaria, Czechia, Estonia, France, Germany, Greece, Israel, Italy, Latvia, Lithuania, Poland, Portugal, Romania, Slovakia, Spain, United Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
First PostedApr 2016
Primary CompletionMar 2018
TodayJul 2026
First PostedApr 27, 2016
Enrollment StartMar 17, 2016
Primary CompletionMar 28, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.2 years ago
Interventions
Secukinumabdrug
Secukinumab was used as commercially available PFS of 150 mg. Patients received PFS at the site and were instructed to administer Secukinumab as needed (300 mg each application).